{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059780","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-05-13T11:23:09+00:00","discovered_at":"2026-05-13T11:25:00.343184+00:00","generated_at":"2026-05-13T11:25:08.272371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts","bullets":["Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.","Net loss $26.1M ($0.20 per share) vs $20.8M ($0.31) a year ago; cash $184.2M, runway into H2 2027.","~600 scripts filled for 560 PSVT patients; ~400 unique prescribers as of April.","Express Scripts national formulary coverage effective March 27, 2026; >25% of commercially insured lives covered.","Phase 3 AFib-RVR trial initiated; first patient enrollment expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059780","json":"https://secwatch.observer/filing/0001104659-26-059780.json","markdown":"https://secwatch.observer/filing/0001104659-26-059780.md","text":"https://secwatch.observer/filing/0001104659-26-059780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:25:08.272371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"923fee8d62b7f7d1168e58bf70f15a21d1b4c9e7","claim":"Milestone Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $0.2 million.","evidence_excerpt":"into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above. · Product revenues were $0.2 million during the three months ended March 31, 2026. There was no product revenue during the three months ended March 31, 2025. · Research and development expense for the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$0.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}